In this opening episode of Inside the Mind of a BioTech Builder, Yves Decadt sets the stage for where biotech is heading next: the convergence of biology, sustainability and long-horizon capital. Rather than treating “green biotech” as a catchphrase, he breaks down what it actually means in practice — from new materials and processes that reduce environmental burden, to platform technologies that can align patient outcomes, planetary impact and investor returns.

Drawing on his 25+ years across Johnson & Johnson, venture-backed biotech, and his advisory work on the initial biotech strategy for NEOM under the Public Investment Fund, Yves explores how the next wave of biotech value creation will be shaped by:

• Shifting regulatory and societal expectations around sustainability,

• The kinds of science and platforms that are most likely to attract serious capital,

• And the difference between stories that “sound green” and businesses that can genuinely scale.

This episode is not about hype cycles. It’s about how founders, boards and investors can read the signal in the green biotech space — understanding where the real opportunities lie, what risks are often underestimated, and how disciplined, ethics-aware leadership can turn sustainability from a marketing angle into a durable investment thesis.